UK Oncology Drugs Market Analysis

UK Oncology Drugs Market Analysis


$ 3999

By 2030, it is anticipated that the UK oncology drugs market will reach a value of $10.6 Bn from $5.1 Bn in 2022, growing at a CAGR of 9.6% during 2022-2030. The companies operating in the oncology drug in the UK market are Immunocore, Adaptimmune, and Oxford BioMedica. The UK oncology drugs market is segmented on the basis of therapy modality and types of cancer. The market is influenced by the National Health Service (NHS) which is responsible for the majority of cancer drug spending in the UK.

ID: IN10GBPH018 CATEGORY: Pharmaceuticals GEOGRAPHY: UK

Buy Now

UK Oncology Drugs Market Analysis Summary

By 2030, it is anticipated that the UK oncology drugs market will reach a value of $10.6 Bn from $5.1 Bn in 2022, growing at a CAGR of 9.6% during 2022-2030. The UK has a large and well-established cancer drug market. The market is driven by an aging population, a growing incidence of cancer, and an increase in the availability of new and innovative cancer treatments. In the UK, in the financial year 2021-2022, it included $235 Mn on research projects focusing on specific cancers and $96 Mn on research that underpins all cancers.

The UK dominates other European nations in the race to discover and create novel oncology therapies. A hub for oncology-focused start-ups, the nation has a thriving venture capital (VC) and start-up scene. The UK cancer drug market is segmented by type of cancer, with the largest segments being breast cancer, lung cancer, and colorectal cancer. Targeted therapies, immunotherapies, and personalized medicine have been the major growth drivers in the market.

UK Oncology Drugs Market Analysis

Market Dynamics

Market Growth Drivers Analysis

The number of cancer medications being created and released onto the market has significantly increased in the UK in recent years. Because of this, the environment for UK-based pharmaceutical companies is now more competitive.

The UK government plays a significant role in the cancer drug market through the National Health Service (NHS) which funds the majority of cancer drug spending in the UK and also by implementing policies that promote the development and use of new cancer treatments.

Market Restraints

Cancer patients may find it difficult to afford the expensive medications they require because of this. Additionally, the high cost of cancer medications can make it difficult for healthcare providers to afford to provide them, straining healthcare budgets. For businesses looking to market new cancer medications, the regulatory approval process for those medications can be time-consuming and expensive.

Competitive Landscape

Key Players

  • Asymchem - Pharma Manufacturing Services (GBR)
  • Immunocore (GBR)
  • Adaptimmune (GBR)
  • Oxford BioMedica (GBR)
  • AstraZeneca
  • GlaxoSmithKline
  • Novartis

Notable Recent Deals

January 2023: BioNTech SE has signed a deal with the UK government to enroll up to 10,000 patients in clinical trials by the end of 2030 for personalized cancer therapies. The multi-year collaboration is focused on cancer immunotherapies based on mRNA or other drug classes, infectious disease vaccines, and investments in expanding the company's footprint in the UK.

Healthcare Policies and Regulatory Landscape

The UK currently participates in a centralized process for drug licensing, managed by the European Medicines Agency (EMA). New drugs are issued through licenses that are granted by the Medicines and Healthcare products Regulatory Agency (MHRA).

The Cancer Drugs Fund (CDF) is a source of funding for cancer drugs in England. In 2016, a new approach to the appraisal and funding of cancer drugs in England has begun operating.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Drugs Market Segmentation

By Drug class

  • Cytotoxic drugs
    • Alkylating agents
    • Antimetabolites
    • Others
  • Targeted drugs
    • Monoclonal antibodies
    • Others
  • Hormonal drugs
  • Others

By Therapy

  • Chemotherapy
  • Targeted therapy
  • Immunotherapy

By Indication

  • Lung cancer
  • Stomach cancer
  • Colorectal cancer
  • Breast cancer
  • Prostate cancer
  • Others

By Dosage form

  • Solid
    • Tablets
    • Capsules
  • Liquid
  • Injectable
    • Prefilled syringes
    • Others

By Distribution channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • ?Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 17 January 2023
Updated by: Shivam Zalke

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up